Zafgen (United States)

A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity‐related risk factors (COR‐II)

Caroline M. Apovian, Louis J. Aronne, Domenica Rubino et al. · Obesity · 2013 · 688 citations · Full text

Effects of <scp>MetAP2</scp> inhibition on hyperphagia and body weight in Prader–Willi syndrome: A randomized, double‐blind, placebo‐controlled trial

Shawn E. McCandless, Jack A. Yanovski, Jennifer Miller et al. · Diabetes Obesity and Metabolism · 2017 · 103 citations · Full text

Ascending dose‐controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women

Thomas E. Hughes, D. D. Kim, Joanne Marjason et al. · Obesity · 2013 · 67 citations

Efficacy and safety of beloranib for weight loss in obese adults: a randomized controlled trial

D. D. Kim, Janakan Krishnarajah, Stephen Lillioja et al. · Diabetes Obesity and Metabolism · 2015 · 62 citations

Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity

Steven R. Smith, Ken Fujioka, Alok Gupta et al. · Diabetes Obesity and Metabolism · 2013 · 58 citations

Bariatric Surgery, Visceral Adipose Tissue, Weight Management +20